Press release
Corporate Press
May 13, 2008

Partnership Award 2007: Evonik Distinguished by Janssen Pharmaceutica

For the third time now, the Geel, Belgium-based pharmaceutical company Janssen Pharmaceutica has distinguished Evonik Industries AG with the Partnership Award for outstanding service as a supplier. A Johnson & Johnson Group (New Brunswick, New Jersey, USA) company, Janssen Pharmaceutica sources custom-made precious-metal catalysts and intermediates from Evonik for the manufacture of pharmaceutical materials. Each year, the pharmaceutical company conducts a critical review of its suppliers based on quality, logistics, costs, and reliability, and uses the results to evaluate the market advantage of working with each supplier.

Evonik also received the Janssen Partnership Award in 2003 and 2006. “We are pleased to have met the rigorous criteria of Janssen Pharmaceutica again in their 2007 review,” said Dr. Hans-Josef Ritzert, head of the Catalysts Business Line of Evonik Industries. The entire workforce from Research and Development, Production, Customer Service, Sales and Marketing have once again managed to combine high product quality with perfect project management and first-class customer service.

Janssen Pharmaceutica employs 4,700 people at three sites in Beerse, Geel and Olen (Belgium). In Geel, the pharmaceutical company produces the materials for 65 percent of the medicinal products of its U.S. parent company Johnson & Johnson. The products are used in human and veterinary medicine.

About Evonik

Evonik Industries is the creative industrial group from Germany which operates in three business areas: Chemicals, Energy and Real Estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our strengths are creativity, specialization, continuous self-renewal, and reliability. Evonik is active in over 100 countries around the world. In its fiscal year 2007 about 43,000 employees generated sales of about €14.4 billion and an operating profit (EBIT) of more than €1.3 billion (preliminary figures).


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.